Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from
Registration statements relating to the ADSs being sold in this offering have been filed with the Securities and Exchange Commission and became effective on October 30, 2018. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
LifeSci Public Relations
Source: Orchard Therapeutics